United Therapeutics Adds Fresh $2 Billion Buyback Authorization
UTHR sits 38% above its 52-week low of $409.07.
Summary
United Therapeutics' board approved an additional $2 billion for share repurchases on October 21, 2026, a new program running through October 21, 2027, on top of the $2 billion authorization it finished spending in September. That prior program ended with a $477.6 million accelerated share repurchase with Citibank, disclosed in an 8-K on September 8, and the ongoing September 2026 accelerated share repurchase, scheduled to terminate in the fourth quarter of 2026 subject to earlier termination or extension, will not reduce the amount available under the new authorization. At a $563.49 share price and roughly $24 billion market value, the new authorization covers a meaningful slice of the float and gives management room to keep retiring stock. Repurchases may be implemented through accelerated share repurchase programs, open market transactions, privately negotiated transactions or other means, and the program does not require the purchase of any minimum number of shares; the company may commence or suspend purchases at any time without prior notice and assumes no obligation to utilize the authorization. The company is also flush with incoming cash: Liquidia owes a $175 million net payment within 30 business days under the October 14 settlement, and the FDA has accepted filings for ralinepag and expanded nebulized Tyvaso. Buybacks at this scale support per-share earnings while the pipeline reviews play out.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The new $2 billion buyback authorization runs through October 21, 2027, and the ongoing September 2026 accelerated share repurchase will not reduce the amount available under it.
- Board Approval — The Board of Directors of United Therapeutics Corporation approved the share repurchase program on October 21, 2026.
- ASR Termination — The accelerated share repurchase entered in September 2026 has a scheduled termination date in the fourth quarter of 2026, subject to earlier termination or extension in accordance with its terms.
- Repurchase Methods — Repurchases may be implemented through accelerated share repurchase programs, open market transactions, privately negotiated transactions or other means.
- Program Flexibility — The program does not require the purchase of any minimum number of shares; the company may commence or suspend purchases at any time without prior notice and assumes no obligation to utilize the authorization.
All 4 details
- ASR entered September 2026 has a scheduled termination date in the fourth quarter of 2026, subject to earlier termination or extension in accordance with its terms.
- Repurchases may be implemented through accelerated share repurchase programs, open market transactions, privately negotiated transactions or other means.
- The program does not require the purchase of any minimum number of shares; the company may commence or suspend purchases at any time without prior notice and assumes no obligation to utilize the authorization.
- Board of Directors of United Therapeutics Corporation approved the share repurchase program on October 21, 2026.
At the time of this announcement, UTHR was trading at $563.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2B. The 52-week trading range was $409.07 to $609.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.